Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Pembrolizumab/Axitinib Improves Survival in Frontline RCC

October 19th 2018

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

October 12th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Dr. O'Donnell Compares Checkpoint Inhibitors in Bladder Cancer

October 12th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Dr. Steinberg on Treatment Approaches in Non-Muscle Invasive Bladder Cancer

October 9th 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses treatment approaches in non-muscle invasive bladder cancer (NMIBC).

Dr. Choueiri Discusses the CANTATA Trial in RCC

October 5th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma.

Immunotherapy Continues to Be Integrated in Metastatic Bladder Cancer

October 4th 2018

Peter O’Donnell, MD, discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma

October 3rd 2018

The dismal prognosis for patients with metastatic renal cell carcinoma has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.

Dr. Stadler on Approved and Investigational Therapies in RCC

October 2nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers

October 2nd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Dr. Sweis on the Frequency of Immune-Related Adverse Events in Kidney Cancer

September 28th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Genomics of Bladder Cancer Remain Largely Unknown

September 26th 2018

Joshua J. Meeks, MD, PhD, discusses the current understanding of genomics in bladder cancer.

Dr. Meeks on the Genomics of Bladder Cancer

September 26th 2018

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the genomics of bladder cancer.

Dr. O'Donnell on the Evolution of Immunotherapy in Metastatic Bladder Cancer

September 25th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Dr. Sweis on Immunotherapy in Genitourinary Cancer

September 22nd 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Dr. Steinberg on BCG Progression in Non-Muscle Invasive Bladder Cancer

September 22nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer

September 19th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

FDA Approval Sought for Erdafitinib in Urothelial Carcinoma

September 19th 2018

A new drug application has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.

Dr. Van Veldhuizen Discusses Combination Therapy in RCC

September 19th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Dr. Singh on the Role of Chemotherapy in Bladder Cancer

September 18th 2018

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.